// App-Quantinova.ai

: Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study

Researchers

Presenter

  • Marius M. Hoeper

Principal Investigators

  • Paul A. Corris

  • Hossein-Ardeschir Ghofrani

  • James R. Klinger

  • David Langleben

  • Robert Naeije

  • Grald Simonneau

  • Pavel Jansa

  • Stephan Rosenkranz

  • Ekkehard Grnig

  • Laura Scelsi

  • Christian Meier

  • Dennis Busse

  • Raymond L. Benza

Medical Centers

  • Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany

  • Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

  • University of Giessen and Marburg Lung Center member of the German Center of Lung Research DZL, Giessen, Germany

  • Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI

  • Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada,

  • Dept. of Cardiology, Erasme University Hospital, Brussels, Belgium

  • Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France,

  • Clinicial Department of Cardiology and Angiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

  • Clinic III for Internal Medicine (Cardiology) and Center for Molecular Medicine (CMMC), and the Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany

  • Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany

  • Division of Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  • Global Medical Affairs, Bayer AG,, Berlin,, Germany

  • Chrestos Concept GmbH & Co. KG, Essen, Germany,

  • Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, United States.

Locations

  • Germany

  • United Kingdom

  • United States

  • Canada

  • Belgium

  • France

  • Czech Republic

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Riociguat

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved